Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
38.77
-0.54 (-1.37%)
At close: Dec 5, 2025, 4:00 PM EST
38.51
-0.26 (-0.67%)
After-hours: Dec 5, 2025, 7:58 PM EST
Cogent Biosciences Employees
Cogent Biosciences had 205 employees as of December 31, 2024. The number of employees increased by 41 or 25.00% compared to the previous year.
Employees
205
Change (1Y)
41
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,435,961
Market Cap
5.90B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 205 | 41 | 25.00% |
| Dec 31, 2023 | 164 | 26 | 18.84% |
| Dec 31, 2022 | 138 | 61 | 79.22% |
| Dec 31, 2021 | 77 | 62 | 413.33% |
| Dec 31, 2020 | 15 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
COGT News
- 5 hours ago - Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - GlobeNewsWire
- 2 days ago - 3 Potential Mid-Cap Biotech Buyout Targets In 2026 - Seeking Alpha
- 22 days ago - Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 24 days ago - Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 - GlobeNewsWire
- 25 days ago - Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside - Seeking Alpha
- 25 days ago - Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewsWire
- 26 days ago - Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy - Seeking Alpha
- 26 days ago - Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript - Seeking Alpha